JPMorgan Chase & Co. Cuts Stake in REGENXBIO Inc. (NASDAQ:RGNX)

JPMorgan Chase & Co. trimmed its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 17.8% in the third quarter, according to its most recent filing with the SEC. The firm owned 2,477,311 shares of the biotechnology company's stock after selling 535,165 shares during the period. JPMorgan Chase & Co. owned approximately 5.00% of REGENXBIO worth $25,987,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. FMR LLC boosted its stake in shares of REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 1,656 shares in the last quarter. nVerses Capital LLC raised its stake in shares of REGENXBIO by 183.3% in the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 2,200 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in REGENXBIO by 64.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company's stock worth $100,000 after buying an additional 3,720 shares in the last quarter. Arizona State Retirement System lifted its holdings in REGENXBIO by 20.6% during the 2nd quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company's stock worth $137,000 after buying an additional 1,997 shares in the last quarter. Finally, Erste Asset Management GmbH bought a new position in REGENXBIO in the third quarter valued at about $140,000. 88.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on RGNX shares. HC Wainwright decreased their price objective on REGENXBIO from $40.00 to $36.00 and set a "buy" rating for the company in a research report on Thursday, November 21st. Morgan Stanley reissued an "overweight" rating and issued a $22.00 price objective on shares of REGENXBIO in a report on Friday, November 15th. StockNews.com upgraded REGENXBIO from a "sell" rating to a "hold" rating in a research note on Friday, September 20th. Chardan Capital reiterated a "buy" rating and set a $52.00 target price on shares of REGENXBIO in a research note on Wednesday, November 20th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $35.00 price objective on shares of REGENXBIO in a research note on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $35.27.

REGENXBIO Stock Down 0.8 %

Shares of REGENXBIO stock traded down $0.07 during trading on Wednesday, hitting $8.29. 1,067,727 shares of the stock traded hands, compared to its average volume of 1,092,765. The stock has a market cap of $410.73 million, a price-to-earnings ratio of -1.65 and a beta of 1.28. REGENXBIO Inc. has a 52 week low of $7.14 and a 52 week high of $28.80. The firm's fifty day moving average is $9.03 and its 200-day moving average is $10.71.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.